Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264157 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects
A Phase 2 study, sponsored by Bio Products Laboratory.
- Completed
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT03264157: Completed Phase 2 study, sponsored by Bio Products Laboratory.
NCT03264157 is a Phase 2 study that has completed, run by Bio Products Laboratory. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03264157, a Phase 2 study, has completed, sponsored by Bio Products Laboratory.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.
Primary Outcome
Non-inferiority in terms of the proportion of subjects with anti-rabies antibody titer of ≥0.5 IU/mL after study drug administration using a non-inferiority margin of 10%.
Interventions
- DRUG HyperRAB
- DRUG HRIG
- BIOLOGICAL RabAvert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2018-07-13 |
| Phase | Phase 2 |
What the finished NCT03264157 record still lists
NCT03264157 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 3 interventions - of which HyperRAB is the first listed.
NCT03264157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03264157 about?
NCT03264157 is a clinical study titled "Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects". A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.
What is the current status of trial NCT03264157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2017-12-08. Estimated completion is 2018-07-13.
What interventions are being tested in trial NCT03264157?
The interventions under investigation include: HyperRAB (DRUG), HRIG (DRUG), RabAvert (BIOLOGICAL).
Who is sponsoring clinical trial NCT03264157?
This trial is sponsored by Bio Products Laboratory, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03264157's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI